TTR and amyloidosis: Overall, 82 ATTR-CA patients were enrolled: 13 (16%) with non-mutated TTR amyloidosis, 66 (80%) with variant TTR amyloidosis (47 with ATTR-V122I (p.Val142Ile), 9 with ATTR-I107V (p.Ile127Val), 2 with ATTR-V30M (p.Val50Met), 8 with other pathogenic transthyretin mutations), and 3 with undetermined genotypes (4%).